Chemical Structure (Ranolazine 01)
Ranolazine Tablet, Film Coated, Extended Release
Product Images NDC 69367-293
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 69367-293). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (500 mg Tablet Bottle Label)
Each extended-release tablet contains 500 mg of Ranolazine. It is recommended to store the tablets at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to ‘Temperature]. Consult dosage and administration instructions for Ranolazine Extended-Release Tablets. The tablets should be swallowed whole, and one should not crush, break, or chew them. Manufactured by ScleGen Pharmaceuticals, Inc. for Westminster Pharmaceuticals, LLC. NDC 69367-203-60. Rev 05/21.*
Principal Display Panel (1000 mg Tablet Bottle Label)
Each extended-release tablet contains 1000 mg of Ranolazine. It should be stored at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). Swallow Ranolazine Extended-Release tablets whole; do not crush, break, or chew. See packaging for dosage and administration. Manufactured by ScieGen Pharmaceuticals, Inc. for Westminster Pharmaceuticals, LLC, Nashville, TN 37217.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
